|
Methods for Treatment of Sepsis and Acute Respiratory Distress Syndrome
LU2025-192
INVENTORS
Youyang Zhao
Colin Evans
SHORT DESCRIPTION
This invention identifies endothelial ALOX15 and its lipid product, 1-Palmitoyl-2-Oleoyl-3-Arachidonoyl-rac-glycerol (POLAR), as key targets for treating sepsis and acute respiratory distress syndrome (ARDS).
BACKGROUND
Sepsis-induced acute lung injury (ALI) and acute...
Published: 12/11/2025
|
Inventor(s):
Keywords(s): ARDS - Acute Respiratory Distress Syndrome, Lung disease, Sepsis, Therapeutics, Vascular disease, Vascular repair
Category(s): Life Sciences > Therapeutics
|
|
Self-assembling peptides with hyaluronic acid binding domains to form hydrogels
NU 2022-016
INVENTORS
Kyle M. Koss
Terrance J. Sereda*
Jason A. Wertheim*
ABSTRACT
A new class of self-assembling peptides with hyaluronic acid-binding domains shows great promise for biomedical applications, particularly in treating injuries, cancer, and enhancing the function of implantable devices. These peptides self-assemble into nanofibers...
Published: 12/11/2025
|
Inventor(s):
Keywords(s): Cancer/Oncology, Drug delivery, Enabling technology, Foreign body response, Implantable devices, Inflammation, Lung disease, Wound healing
Category(s): Life Sciences > Therapeutics
|
|
Novel Biomarker for Lung Disease Diagnosis and Monitoring
NU2022-232
INVENTORS
Ankit Bharat*
Yuanqing Yan
SHORT DESCRIPTION
A robust and reliable biomarker for diagnosing and predicting lung disease
ABSTRACT
The lack of robust biomarkers for lung diseases is a pressing challenge. A team of scientists at Northwestern University has identified the protein serine protease inhibitor Kazal-type 1 (SPINK1)...
Published: 11/6/2025
|
Inventor(s):
Keywords(s): Cardio-Pulmonary, Diagnostics, Lung disease
Category(s): Life Sciences > Biomarkers & Biomedical Research Tools
|
|
Novel Therapeutic Target for Treating Lung Disease
NU2022-231
INVENTORS
Ankit Bharat*
Yuanqing Yan
SHORT DESCRIPTION
A novel protein target for treating chronic and acute lung diseases
ABSTRACT
Lung diseases caused by pulmonary fibrosis can be fatal, and the currently approved drugs for treating pulmonary fibrosis, including Nintedanib and Pirfenidone, only slow down the disease progression....
Published: 11/6/2025
|
Inventor(s):
Keywords(s): Cardio-Pulmonary, Lung disease
Category(s): Life Sciences > Therapeutics
|